Journal article
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study.
Abstract
BACKGROUND: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate the effect of romosozumab on the radiographic and clinical outcomes of surgical fixation of tibial diaphyseal fractures.
METHODS: Patients (18 to 82 years old) were randomized 3:1:1:1:1:1:1:1:1:1 to a placebo or 1 of 9 …
Authors
Bhandari M; Schemitsch EH; Karachalios T; Sancheti P; Poolman RW; Caminis J; Daizadeh N; Dent-Acosta RE; Egbuna O; Chines A
Journal
Journal of Bone and Joint Surgery, Vol. 102, No. 16, pp. 1416–1426
Publisher
Wolters Kluwer
Publication Date
August 19, 2020
DOI
10.2106/jbjs.19.01008
ISSN
0021-9355
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalBone Density Conservation AgentsCombined Modality TherapyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFracture FixationFracture HealingHumansInjections, SubcutaneousMaleMiddle AgedTibial FracturesTreatment OutcomeYoung Adult